Alnylam Pharmaceuticals Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$713.00 | Lczxgp | Kwcxbkzy |
Alnylam Earnings: Strong Commercial Execution Drives Growth; Pipeline Continues To Make Progress
Alnylam reported strong first-quarter results highlighted by $276 million in net product revenue, representing 48% year-over-year growth. Amvuttra, which received FDA approval in June 2022 for hATTR amyloidosis with polyneuropathy, is continuing its strong launch with over $102 million in sales, accounting for 27% of the quarter’s sales. Alnylam’s results are largely tracking our forecasts, and we maintain our fair value estimate of $199 per share. We view shares as fairly valued, and the stock is trading in 3-star territory. We maintain our narrow economic moat rating and positive moat trend.